

The Commission subsequently issued its final determinations that an industry in the United States was materially injured by reason of imports of PC strand from Argentina, Colombia, Egypt, Netherlands, Saudi Arabia, Taiwan, Turkey, and the United Arab Emirates provided for in subheading 7312.10.30 of the Harmonized Tariff Schedule of the United States (“HTSUS”) that have been found by the Commerce to be sold in the United States at LTFV and subsidized by the government of Turkey. Commerce has issued final affirmative antidumping duty determinations with respect to PC strand from Indonesia,³ Italy,⁴ Malaysia,⁵ South Africa,⁶ Spain,⁷ Tunisia,⁸ and Ukraine.⁹ Accordingly, the Commission currently is issuing a supplemental schedule for its antidumping duty investigations on imports of PC strand from Indonesia, Italy, Malaysia, South Africa, Spain, Tunisia, and Ukraine. This supplemental schedule is as follows: the deadline for filing supplemental party comments on Commerce’s final antidumping duty determinations is April 19, 2021. Supplemental party comments may address only Commerce’s final antidumping duty determinations regarding imports of PC strand from Indonesia, Italy, Malaysia, South Africa, Spain, Tunisia, and Ukraine. These supplemental final comments may not contain new factual information and may not exceed five (5) pages in length. The supplemental staff report in the final phase of these investigations regarding subject imports from Indonesia, Italy, Malaysia, South

Africa, Spain, Tunisia, and Ukraine will be placed in the nonpublic record on May 4, 2021; and a public version will be issued thereafter.

For further information concerning these investigations see the Commission’s notice cited above and the Commission’s Rules of Practice and Procedure, part 201, subparts A and B (19 CFR part 201), and part 207, subparts A and C (19 CFR part 207). Additional written submissions to the Commission, including requests pursuant to section 201.12 of the Commission’s rules, shall not be accepted unless good cause is shown for accepting such submissions, or unless the submission is pursuant to a specific request by a Commissioner or Commission staff.

In accordance with sections 201.16(c) and 207.3 of the Commission’s rules, each document filed by a party to the investigations must be served on all other parties to the investigations (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Authority: : These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.21 of the Commission’s rules.

By order of the Commission.

Issued Date: April 15, 2021.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2021–08178 Filed 4–20–21; 8:45 am]

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337–TA–1262]

Certain Skin Rejuvenation Resurfacing Devices, Components Thereof, and Products Containing the Same; Institution of Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on March 16, 2021, under section 337 of the Tariff Act of 1930, as amended, on behalf of InMode Ltd. of Israel and Invasix Inc. d/b/a InMode of Lake Forest, California. Supplements to the complaint were filed on April 1 and April 5, 2021. The complaint alleges violations of section 337 based upon the importation into the United States, the

sale for importation, and the sale within the United States after importation of certain skin rejuvenation resurfacing devices, components thereof, and products containing the same by reason of infringement of a claim of U.S. Patent No. 10,799,285 (“the ‘285 patent”). The complaint further alleges that an industry in the United States exists as required by the applicable Federal Statute. The complainants request that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders.

ADDRESSES: The complaint, except for any confidential information contained therein, may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205–2000. General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>.

FOR FURTHER INFORMATION CONTACT:

Katherine Hiner, Office of the Secretary, Docket Services Division, U.S. International Trade Commission, telephone (202) 205–1802.

SUPPLEMENTARY INFORMATION:

Authority:

The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in section 210.10 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.10 (2020).

Scope of Investigation: Having considered the complaint, the U.S. International Trade Commission, on April 15, 2021, ordered that—

(1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain products identified in paragraph (2) by reason of infringement of claim 1 of the ‘285 patent; and whether an industry in the United States exists as required by subsection (a)(2) of section 337;

(2) Pursuant to section 210.10(b)(1) of the Commission’s Rules of Practice and Procedure, 19 CFR 210.10(b)(1), the

³ *Prestressed Concrete Steel Wire Strand from Indonesia: Final Affirmative Determination of Sales at Less Than Fair Value, and Final Affirmative Determination of Critical Circumstances, In Part*, 86 FR 18495, April 9, 2021.

⁴ *Prestressed Concrete Steel Wire Strand from Italy: Final Affirmative Determination of Sales at Less Than Fair Value, and Final Negative Determination of Critical Circumstances*, 86 FR 18505, April 9, 2021.

⁵ *Prestressed Concrete Steel Wire Strand from Malaysia: Final Affirmative Determination of Sales at Less Than Fair Value*, 86 FR 18502, April 9, 2021.

⁶ *Prestressed Concrete Steel Wire Strand from South Africa: Final Affirmative Determination of Sales at Less Than Fair Value*, 86 FR 18497, April 9, 2021.

⁷ *Prestressed Concrete Steel Wire Strand from Spain: Final Affirmative Determination of Sales at Less Than Fair Value, and Final Negative Determination of Critical Circumstances*, 86 FR 18512, April 9, 2021.

⁸ *Prestressed Concrete Steel Wire Strand from Tunisia: Final Affirmative Determination of Sales at Less Than Fair Value*, 86 FR 18508, April 9, 2021.

⁹ *Prestressed Concrete Steel Wire Strand from Ukraine: Final Affirmative Determination of Sales at Less Than Fair Value, and Final Negative Determination of Critical Circumstances*, 86 FR 18498, April 9, 2021.

plain language description of the accused products or category of accused products, which defines the scope of the investigation, is “skin resurfacing devices, punctile resurfacing systems, radio-frequency microneedling systems, and components of each”;

(3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served:

(a) The complainants are:

InMode Ltd., Tavor Building Shaar
Yokneam, P.O. Box 533, Yokneam
2069206, Israel

Invasix Inc. d/b/a InMode, 20996 Bake
Parkway, Suite 106, Lake Forest, CA
92630

(b) The respondents are the following entities alleged to be in violation of section 337, and the parties upon which the complaint is to be served:

ILOODA Co., Ltd., 120 Jangan-ro
458beon-gil, Jangan-gu Suwon, 16200,
Republic of Korea

Cutera, Inc., 3240 Bayshore Boulevard,
Brisbane, CA 94005

(4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge.

The Office of Unfair Import Investigations is not a party to this investigation.

Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), as amended in 85 FR 15798 (March 19, 2020), such responses will be considered by the Commission if received not later than 20 days after the date of service by the complainants of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown.

Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the

issuance of an exclusion order or a cease and desist order or both directed against the respondent.

By order of the Commission.

Issued: April 15, 2021.

Lisa Barton

Secretary to the Commission.

[FR Doc. 2021–08159 Filed 4–20–21; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–823]

Bulk Manufacturer of Controlled Substances Application: Research Triangle Institute

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Notice of application.

SUMMARY: Research Triangle Institute, has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before June 21, 2021. Such persons may also file a written request for a hearing on the application on or before June 21, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on March 18, 2021, Research Triangle Institute, 3040 East Cornwallis Road, Hermann Building, Room 106, Research Triangle Park, North Carolina 27709, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Tetrahydrocannabinols	7370	I

The company plans to bulk manufacture the listed controlled substance synthetically only for distribution to its customers for research and analytical reference standards. No

other activity for this drug code is authorized for this registration.

William T. McDermott,

Assistant Administrator.

[FR Doc. 2021–08165 Filed 4–20–21; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. 17–11]

Mark A. Wimbley, M.D.; Decision and Order

I. Procedural History

On October 20, 2016, a former Assistant Administrator, Diversion Control Division, Drug Enforcement Administration (hereinafter, DEA or Government), issued an Order to Show Cause (hereinafter, OSC) to Mark A. Wimbley, M.D. (hereinafter, Respondent), of Costa Mesa, California. Administrative Law Judge (hereinafter, ALJ) Exhibit (hereinafter, ALJX) 1, (OSC) at 1. The OSC proposed the revocation of and denial of any pending application to modify or renew Respondent’s Certificate of Registration No. BW5359004 pursuant to 21 U.S.C. 823(f) and 824(a)(4) for the reason that “[his] continued registration is inconsistent with the public interest, as that term is defined in 21 U.S.C. 823(f).” *Id.*

The OSC alleged that Respondent issued prescriptions for controlled substances to four¹ individuals outside the usual course of the professional practice in violation of 21 CFR 1306.04(a) and in violation of California law and the minimum standards of medical practice in California. *Id.* at 2–8. Specifically, the OSC alleged that Respondent “issued these orders for controlled substances without meeting the minimal medical standards required under California law, including those listed in the ‘Guide to the Laws Governing the Practice of Medicine by Physicians and Surgeons,’ Medical Board of California, 7th Ed. 2013.” *Id.* at 7. Additionally, the OSC alleged that for the four listed patients, Respondent failed to do one or more of the following:

perform a physical examination; take appropriate medical history; assess pain, physical and psychological function; make an assessment of any underlying or coexisting diseases or conditions; confirm the patient was taking previously prescribed

¹ The Government withdrew allegations related to one of the patients in its Supplemental Prehearing Statement, so this matter is limited to three patients. ALJX 7, 7–8.